Published in Cancer Weekly, August 18th, 1997
PEG-INTRON A is a modified form of Schering-Plough's INTRON A (interferon alfa-2b, recombinant), developed by Enzon to have longer-acting properties. In this Phase III program, PEG-INTRON A administered once a week, is compared to INTRON A at the licensed regimen, which is currently three times a week. Enzon currently has two U.S. Food and Drug Administration approved products on the market that use this PEG Modification technology.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.